Mixed impact of Xpert® MTB/RIF on tuberculosis diagnosis in Cambodia

• Published in: Public health action 2016-06, Vol.6 (2), p.129-135
• Main Authors: Auld, S. C., Moore, B. K., Kyle, R. P., Eng, B., Nong, K., Pevzner, E. S., Eam, K. K., Eang, M. T., Killam, W. P.
• Format: Article
• Language: English
• Subjects: Drug Resistance; HIV; Mdr-Tb; Original; Point-Of-Care Testing
• ISSN: 2220-8372; 2220-8372
• DOI: 10.5588/pha.16.0001

Setting: National Tuberculosis (TB) Program sites in northwest Cambodia.Objective: To evaluate the impact of Xpert® MTB/RIF at point of care (POC) as compared to non-POC sites on the diagnostic evaluation of people living with the human immunodeficiency virus (PLHIV) with TB symptoms and patients with possible multidrug-resistant (MDR) TB.Design: Observational cohort of patients undergoing routine diagnostic evaluation for TB following the rollout of Xpert.Results: Between October 2011 and June 2013, 431 of 822 (52%) PLHIV with TB symptoms and 240/493 (49%) patients with possible MDR-TB underwent Xpert. Xpert was more likely to be performed when available as POC. A smaller proportion of PLHIV at POC sites were diagnosed with TB than at non-POC sites; however, at POC sites, a higher proportion of those diagnosed with TB were bacteriologically positive. There was poor agreement between Xpert and other tests such as smear microscopy and culture. Overall, the evaluation of patients with possible MDR-TB increased following Xpert rollout, yet for patients confirmed as having drug resistance on drug susceptibility testing, only 46% had rifampin resistance that would be identified with Xpert.Conclusion: Although utilization of Xpert was low, it may have contributed to an increase in evaluations for possible MDR-TB and a decline in empiric treatment for PLHIV when available as POC.